文献速递心律失常血脂与心血管预防

阿哌沙班与华法林治疗房颤患者非大出血的比较

Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation.
PubMed 文献 · Heart · 2016-10-24

非大出血发生率是大出血的3倍(12.1% vs 3.8%),阿哌沙班组非大出血发生率低于华法林组(每100患者年6.4 vs 9.4,调整HR 0.69,95%CI 0.63-0.75)。临床相关非大出血(CRNM)与全因死亡(调整HR 1.70,95%CI 1.32-2.18)和后续大出血(调整HR 2.18,95%CI 1.56-3.04)风险独立相关。

要点

  • 非大出血发生率是大出血的3倍,阿哌沙班较华法林显著降低非大出血风险。
  • CRNM出血独立增加死亡和后续大出血风险,任何严重程度的出血均需重视。
  • 非大出血最常见部位为血尿、鼻出血、胃肠道、血肿和瘀斑。

核心结论

  • 在ARISTOTLE试验中,非大出血常见,且阿哌沙班较华法林显著降低非大出血发生率。
  • CRNM出血独立与死亡和后续大出血风险增加相关,提示非大出血(包括轻微出血)可能并不轻微。

研究设计与样本

  • 非大出血定义为首次发生的临床相关非大出血(CRNM)或轻微出血,且之前无大出血事件。

主要发现

  • 非大出血发生率12.1%,大出血发生率3.8%。
  • 阿哌沙班组非大出血发生率为每100患者年6.4,华法林组为9.4(调整HR 0.69,95%CI 0.63-0.75)。
  • 非大出血最常见部位:血尿16.4%、鼻出血14.8%、胃肠道13.3%、血肿11.5%、瘀斑10.1%。
  • 华法林组与阿哌沙班组非大出血患者接受医疗或手术干预的比例相似(24.7% vs 24.5%)。
  • 华法林组较阿哌沙班组抗栓治疗改变(58.6% vs 50.0%)和永久停药(5.1% vs 3.6%,p=0.10)数值上更高。

关键数值与推荐

  • CRNM出血独立与全因死亡风险增加相关(调整HR 1.70,95%CI 1.32-2.18)。
  • CRNM出血独立与后续大出血风险增加相关(调整HR 2.18,95%CI 1.56-3.04)。

临床怎么用

  • 房颤抗凝治疗中应关注任何严重程度的出血,包括非大出血和轻微出血。
  • 发生CRNM出血的患者死亡和后续大出血风险更高,需加强监测和管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We describe the incidence, location and management of non-major bleeding, and assess the association between non-major bleeding and clinical outcomes in patients with atrial fibrillation (AF) receiving anticoagulation therapy enrolled in Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE). METHODS: We included patients who received ≥1 dose of study drug (n=18 140). Non-major bleeding was defined as the first bleeding event considered to be clinically relevant non-major (CRNM) or minor bleeding, and not preceded by a major bleeding event. RESULTS: Non-major bleeding was three times more common than major bleeding (12.1% vs 3.8%). Like major bleeding, non-major bleeding was less frequent with apixaban (6.4 per 100 patient-years) than warfarin (9.4 per 100 patient-years) (adjusted HR 0.69, 95% CI 0.63 to 0.75). The most frequent sites of non-major bleeding were haematuria (16.4%), epistaxis (14.8%), gastrointestinal (13.3%), haematoma (11.5%) and bruising/ecchymosis (10.1%). Medical or surgical intervention was similar among patients with non-major bleeding on warfarin versus apixaban (24.7% vs 24.5%). A change in antithrombotic therapy (58.6% vs 50.0%) and permanent study drug discontinuation (5.1% (61) vs 3.6% (30), p=0.10) was numerically higher with warfarin than apixaban. CRNM bleeding was independently associated with an increased risk of overall death (adjusted HR 1.70, 95% CI 1.32 to 2.18) and subsequent major bleeding (adjusted HR 2.18, 95% CI 1.56 to 3.04). CONCLUSIONS: In ARISTOTLE, non-major bleeding was common and substantially less frequent with apixaban than with warfarin. CRNM bleeding was independently associated with a higher risk of death and subsequent major bleeding. Our results highlight the importance of any severity of bleeding in patients with AF treated with anticoagulation therapy and suggest that non-major bleeding, including minor bleeding, might not be minor. TRIAL REGISTRATION NUMBER: NCT00412984; post-results.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Bahit MC, Lopes RD, Wojdyla DM, et al. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart. 2016. PMID: 27798052. doi:10.1136/heartjnl-2016-309901

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。